OKYO Pharma Announces Chairman and Founder Acquires Shares

Summary by AI BETAClose X

OKYO Pharma Limited announced that Gabriele Cerrone, Executive Chairman, through Panetta Partners Limited, acquired 82,018 ordinary shares on NASDAQ, increasing his total holding to 10,464,695 shares. This acquisition by a key executive could signal confidence in the company's development of urcosimod, a novel drug candidate for neuropathic corneal pain and dry eye disease, which has recently completed a Phase 2 trial for neuropathic corneal pain and showed statistical significance in a Phase 2 trial for dry eye disease.

Disclaimer*

UK 100

Latest directors dealings